

# CITATION REPORT

List of articles citing

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting

DOI: 10.1371/journal.pone.0178420  
PLoS ONE, 2017, 12, e0178420.

**Source:** <https://exaly.com/paper-pdf/87045520/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
62	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 831-844	4.4	78
61	Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 3519-3529	4.4	32
60	Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 360-370	4.9	19
59	Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 241-252	3.2	4
58	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. <i>Archivos De Bronconeumologia</i> , <b>2018</b> , 54, 10-17	0.7	
57	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. <i>Archivos De Bronconeumologia</i> , <b>2018</b> , 54, 10-17	0.7	14
56	Leveraging Treatment Patterns to Predict Survival of Patients with Advanced Non-Small-Cell Lung Cancer. <b>2018</b> ,		1
55	Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigaci3 Divulgaci3 Oncol3gica experience. <i>European Journal of Cancer Care</i> , <b>2018</b> , 27, e12950	2.4	0
54	Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 1191-1205	2.4	44
53	From hype to reality: data science enabling personalized medicine. <i>BMC Medicine</i> , <b>2018</b> , 16, 150	11.4	139
52	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 694-708	19.4	151
51	Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. <i>Lung Cancer</i> , <b>2019</b> , 135, 196-204	5.9	39
50	Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer. <i>Journal of Biomedical Informatics</i> , <b>2019</b> , 100, 103335	10.2	8
49	Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. <i>Future Oncology</i> , <b>2019</b> , 15, 3491-3502	3.6	32
48	New options for combination therapy for advanced non-squamous NSCLC. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 1095-1107	3.8	7
47	Data challenges for evaluating new treatments. <i>Cancer</i> , <b>2019</b> , 125, 2528-2531	6.4	
46	First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz020	4.6	4

45	Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 287-296.e4	4.9	21
44	A text-mining approach to obtain detailed treatment information from free-text fields in population-based cancer registries: A study of non-small cell lung cancer in California. <i>PLoS ONE</i> , <b>2019</b> , 14, e0212454	3.7	8
43	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. <i>Medicina (Lithuania)</i> , <b>2019</b> , 55,	3.1	
42	Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. <i>Immunotherapy</i> , <b>2019</b> , 11, 1463-1478	3.8	22
41	Validity of Natural Language Processing for Ascertainment of and Test Results in SEER Cases of Stage IV Non-Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , <b>2019</b> , 3, 1-15	5.2	6
40	A very rare presentation of lung cancer: Metastases to the distal phalanx of index-case report. <i>Medicine (United States)</i> , <b>2019</b> , 98, e17892	1.8	1
39	Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1241-1256	2.5	34
38	Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. <i>PLoS ONE</i> , <b>2019</b> , 14, e0209709	3.7	22
37	Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 535-542	2.5	8
36	Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review. <i>PharmacoEconomics - Open</i> , <b>2020</b> , 4, 381-388	2.1	0
35	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 793-803	2.2	12
34	The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 54	6.3	14
33	Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233768	3.7	1
32	The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2020</b> , 47, 1083-1091	3	9
31	Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 363-372	5.9	8
30	Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis. <i>BMC Cancer</i> , <b>2020</b> , 20, 260	4.8	6
29	Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 671-690	4.9	9
28	Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 56-65	5.2	3

27	An Automated Line-of-Therapy Algorithm for Adults With Metastatic Non-Small Cell Lung Cancer: Validation Study Using Blinded Manual Chart Review. <i>JMIR Medical Informatics</i> , <b>2021</b> , 9, e29017	3.6	
26	Prognostic role of epidermal growth factor receptor mutation status in patients with de novo lung adenocarcinoma.. <i>Translational Cancer Research</i> , <b>2021</b> , 10, 1549-1558	0.3	
25	Automated Line-of-Therapy Algorithm for Adults with Metastatic Non-Small Cell Lung Cancer: Validation Study Using Blinded Manual Chart Review (Preprint).		
24	Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. <i>JMIR Cancer</i> , <b>2021</b> , 7, e23161	3.2	0
23	Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. <i>Scientific Reports</i> , <b>2021</b> , 11, 9222	4.9	4
22	Evaluating eligibility criteria of oncology trials using real-world data and AI. <i>Nature</i> , <b>2021</b> , 592, 629-633	50.4	20
21	Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. <i>BMC Cancer</i> , <b>2021</b> , 21, 731	4.8	0
20	Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR). <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3059-3070	4.4	
19	Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2021</b> ,	1.9	0
18	Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	0
17	Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 849-858	5.2	2
16	Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China. <i>European Journal of Hospital Pharmacy</i> , <b>2020</b> ,	1.6	7
15	First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	6
14	Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature. <i>Molecular and Clinical Oncology</i> , <b>2019</b> , 11, 439-446	1.6	10
13	Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 469-477	7.3	10
12	Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database. <i>Current Oncology</i> , <b>2021</b> , 28, 4213-4222	2.8	2
11	First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study. <i>Cancer Medicine</i> , <b>2021</b> , 10, 8127-8137	4.8	1
10	Data Integration to Improve Real-world Health Outcomes Research for NonSmall Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration (Preprint).		

9	Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With 80% Expression of Programmed Cell Death-Ligand 1.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 834761	5.3	0
8	Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	0
7	Generalizability of ORIENT-11 trial results to a US standard of care cohort with advanced non-small-cell lung cancer.. <i>Future Oncology</i> , <b>2022</b> ,	3.6	0
6	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. <b>2022</b> , 14, 4481		0
5	Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies. <b>2022</b> , 33, 100648		1
4	Patterns of chemotherapy use and outcomes in advanced non-small-cell lung cancer in relation to age in England: An analysis of the Systemic Anti-Cancer Treatment (SACT) dataset.		0
3	APOBEC Mutational Signatures in Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. <b>2022</b> ,		2
2	Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices. 12,		2
1	Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018. <b>2023</b> , 23,		0